MAFLD健康影响受脂肪肝相关遗传变异叠加放大
MAFLD与肝癌、肝硬化、其他肝病、心血管病、肾病及癌症风险升高独立相关,高遗传风险评分放大其对肝脏结局的影响。
要点
- MAFLD患者肝硬化风险为无MAFLD者的2.77倍(95%CI 2.29-3.36)。
- MAFLD患者肝癌风险升高1.59倍(95%CI 1.28-1.98),心血管病风险升高1.39倍。
- 高遗传风险评分放大MAFLD对肝脏结局的影响,PNPLA3、TM6SF2和MBOAT7起主要作用。
核心结论
- MAFLD独立增加肝内和肝外事件风险,脂肪肝相关遗传变异可放大该效应。
主要发现
- MAFLD与肝癌多变量调整HR 1.59(95%CI 1.28-1.98)、肝硬化2.77(2.29-3.36)、其他肝病2.09(1.95-2.24)相关。
- MAFLD与心血管病HR 1.39(1.34-1.44)、肾病1.56(1.48-1.65)、癌症1.07(1.05-1.10)相关。
- 高遗传风险评分放大MAFLD对肝脏事件的影响,PNPLA3、TM6SF2和MBOAT7变异起主要作用。
- 正常体重的MAFLD患者肝脏结局风险仍升高,但遗传因素似乎不影响该亚群风险。
临床怎么用
- 对MAFLD患者应评估肝内和肝外事件风险,尤其关注肝硬化、肝癌及心血管和肾脏疾病。
- 可考虑结合脂肪肝相关遗传变异评估肝脏结局风险分层。
- 正常体重MAFLD患者也需监测肝脏结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly proposed disease category that derived from non-alcoholic fatty liver disease. The impact of MAFLD on health events has not been investigated. METHODS: UK Biobank participants were diagnosed for whether MAFLD presented at baseline. Five genetic variants (PNPLA3 rs738409 C/G, TM6SF2 rs58542926 C/T, GCKR rs1260326 T/C, MBOAT7 rs641738 C/T, and HSD17B13 rs72613567 T/TA) were integrated into a genetic risk score (GRS). Cox proportional hazard model was used to examine the association of MAFLD with incident diseases. RESULTS: A total of 160 979 (38.0%, 95% confidence interval [CI] 37.9%, 38.2%) participants out of 423 252 were diagnosed as MAFLD. Compared with participants without MAFLD, MAFLD cases had multivariate adjusted hazard ratio (HR) for liver cancer of 1.59 (95% CI, 1.28, 1.98), cirrhosis of 2.77 (2.29, 3.36), other liver diseases of 2.09 (1.95, 2.24), cardiovascular diseases of 1.39 (1.34, 1.44), renal diseases of 1.56 (1.48, 1.65), and cancers of 1.07 (1.05, 1.10). The impact of MAFLD, especially on hepatic events, was amplified by high GRS, of which the genetic variations in PNPLA3, TM6SF2, and MBOAT7 play the principal roles. MAFLD case with normal body weight is also associated with an increased risk of hepatic outcomes, but the genetic factor seems do not influence the risk in this subpopulation. CONCLUSIONS: MAFLD is independently associated with an increased risk of both intrahepatic and extrahepatic events. Fatty liver disease related genetic variants amplify the effect of MAFLD on disease outcomes.
引用
- Liu Z, Suo C, Shi O, et al. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants. Clin Gastroenterol Hepatol. 2020. PMID: 33387670. doi:10.1016/j.cgh.2020.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。